Please use this identifier to cite or link to this item:
|Title:||Myelodysplasia, vasculitis and anti-neutrophil cytoplasm antibodies.|
|Authors:||Savige, Judy A;Chang, L;Smith, C L;Duggan, J C|
|Affiliation:||University Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia.|
|Citation:||Leukemia & Lymphoma; 9(1-2): 49-54|
|Abstract:||A cutaneous or systemic vasculitis occurs in myelodysplasia as well as in myeloproliferative and lymphoproliferative disorders. The most common lesion is a leucocytoclastic vasculitis, with neurological or joint involvement occurring less often. The vasculitis may appear contemporaneously with or precede the clinical onset of the blood dyscrasia. Occasionally the lesions respond dramatically to the use of steroids but in general, patients with vasculitis have a worse prognosis than those with uncomplicated myelodysplasia. Vasculitis and myelodysplasia appear together too often for the association to be coincidental and the vasculitis in most cases cannot be attributed to intercurrent infections, therapeutic agents or a pre-existing rheumatological disorder. While autoantibodies are frequently present in myelodysplasia, and ANA and anti-neutrophil cytoplasm antibodies (ANCA) are found in other vasculitides, neither of these antibodies is associated with the vasculitis of myelodysplasia. There has however been one report of ANCA in Sweet's syndrome a non-vasculitic skin condition that also occurs in the myelodysplastic syndromes.|
|Internal ID Number:||8477201|
Alkylating Agents.adverse effects
Anemia, Refractory, with Excess of Blasts.epidemiology
Myelodysplastic Syndromes.chemically induced.complications.immunology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.